• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    HeartSciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    3/13/25 4:16:43 PM ET
    $HSCS
    Industrial Specialties
    Health Care
    Get the next $HSCS alert in real time by email
    8-K
    false00014684920001468492us-gaap:WarrantMember2025-03-132025-03-1300014684922025-03-132025-03-130001468492us-gaap:CommonStockMember2025-03-132025-03-13

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): March 13, 2025

     

     

    HEARTSCIENCES INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Texas

    001-41422

    26-1344466

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    550 Reserve Street, Suite 360

     

    Southlake, Texas

     

    76092

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 682 237-7781

     

    n/a

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock

     

    HSCS

     

    The Nasdaq Stock Market LLC

    Warrants

     

    HSCSW

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On March 13, 2025, HeartSciences Inc. fka Heart Test Laboratories, Inc. (the "Company") issued a press release providing information regarding the Company's financial and operating results for the quarter ended January 31, 2025, and other business updates. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

    The information contained in Item 2.02 of this report and Exhibit 99.1 to this report shall not be deemed to be "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be incorporated by reference into any filings made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

     

    Exhibit

    No.

    Description

    99.1

     

    Press Release dated March 13, 2025

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    HEART TEST LABORATORIES, INC.

     

     

     

     

    Date:

    March 13, 2025

    By:

    /s/ Andrew Simpson

     

     

    Name:

    Title:

    Andrew Simpson
    President, Chief Executive Officer and Chairman of the Board of Directors

     


    Get the next $HSCS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HSCS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HSCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Heart Test Laboratories Inc.

      SC 13G - Heart Test Laboratories, Inc. (0001468492) (Subject)

      12/11/23 8:30:12 AM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Heart Test Laboratories Inc.

      SC 13G - Heart Test Laboratories, Inc. (0001468492) (Subject)

      11/27/23 4:02:41 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form SC 13D filed by Heart Test Laboratories Inc.

      SC 13D - Heart Test Laboratories, Inc. (0001468492) (Subject)

      6/14/23 5:06:17 PM ET
      $HSCS
      Industrial Specialties
      Health Care

    $HSCS
    Financials

    Live finance-specific insights

    See more
    • HeartSciences Issues Investor Update Highlighting Recent Key Achievements and Positive Developments

      Entered into Transformative Agreements with Icahn Mount Sinai Filed FDA Pre-Submission Request to Change to 510(k) Submission from De Novo following Issuance of New Classification for AI ECG by FDA To host conference call on Wednesday, October 25, 2023 Southlake, TX, Oct. 19, 2023 (GLOBE NEWSWIRE) --  Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an AI-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced a conference call to update investors on recent key achievements and positive developments. The conference call will be host

      10/19/23 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care

    $HSCS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone

      Southlake, TX, May 29, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company focused on transforming ECGs/EKGs to enable earlier detection of heart disease, today announced the signing of its first commercial customer for the MyoVista Insights™ platform: Westcliffe Health Innovations, based in the United Kingdom. This milestone follows the recent launch of MyoVista Insights and the initiation of an early adopter program for reference sites earlier this month. Westcliffe Health Innovations provides cardiology services to the U.K. National Health Service (NHS) in the Bradfor

      5/29/25 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care
    • Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

      MIAMI, May 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting Today, May 21, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go ba

      5/21/25 7:00:00 AM ET
      $ASPI
      $ATCH
      $CIA
      $CLNN
      Major Chemicals
      Industrials
      Finance: Consumer Services
      Finance
    • HeartSciences' CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025

      Southlake, TX, May 20, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson will deliver a live presentation and participate in a Q&A session at the Emerging Growth Conference 82. Event Details: Date: Wednesday, May 21, 2025 Time: 10:15 AM EDT | 7:15 AM PDT Format: Virtual presentation with live Q&A Registration To attend this live, interactive online event, please register though: Emerging Growth Conference 82 This event prov

      5/20/25 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care

    $HSCS
    Leadership Updates

    Live Leadership Updates

    See more
    • HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board

      Southlake, TX, May 07, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Dr. Girish Nadkarni, MD, Dr. Joshua Lampert, MD, and Dr. Akhil Vaid, MBBS, to its Scientific Advisory Board. These appointments underscore HeartSciences' commitment to advancing and transforming data-driven AI-ECG technology. "We are honored to welcome Dr. Girish Nadkarni, Dr. Joshua Lampert, and Dr. Akhil Vaid to our Scientific Advisory Board," said Andrew Simpson, CEO of HeartScien

      5/7/25 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences Adds Key Advisor to its Scientific Advisory Board

      Southlake, TX, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Dr. Partho P. Sengupta, MD, MBBS, FACC, to its Scientific Advisory Board. "Dr. Sengupta has been an author on multiple peer reviewed AI-ECG publications using the Company's technology and we are delighted to have someone of his caliber join our growing Scientific Advisory Board," said Andrew Simpson, CEO of HeartSciences. "Dr. Sengupta has

      2/26/24 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences Expands its Scientific Advisory Board

      Southlake, TX, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Jordan B. Strom M.D., M.Sc., to its Scientific Advisory Board. "Dr. Strom has been assisting us in recent interactions with the FDA and we are delighted to welcome him to our Scientific Advisory Board as we prepare for FDA submission of our MyoVista device and cloud platform, in addition to algorithms licensed from the Icahn School of Medi

      2/12/24 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care

    $HSCS
    SEC Filings

    See more
    • HeartSciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - HeartSciences Inc. (0001468492) (Filer)

      5/28/25 4:51:58 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

      8-K - HeartSciences Inc. (0001468492) (Filer)

      5/19/25 5:29:21 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form 253G2 filed by HeartSciences Inc.

      253G2 - HeartSciences Inc. (0001468492) (Filer)

      5/15/25 5:00:04 PM ET
      $HSCS
      Industrial Specialties
      Health Care

    $HSCS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Bent Bruce

      4 - HeartSciences Inc. (0001468492) (Issuer)

      1/23/25 4:30:07 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Officer Hilz Mark T

      4 - HeartSciences Inc. (0001468492) (Issuer)

      1/21/25 7:21:18 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Wells David R.

      4 - HeartSciences Inc. (0001468492) (Issuer)

      1/21/25 5:17:26 PM ET
      $HSCS
      Industrial Specialties
      Health Care